8 research outputs found
Clinicopathologic features by HER2 status.
<p>Abbreviation: OGD, oesophagogastroduodenoscopy.</p
Progression-free survival analysis.
<p>Abbreviation: HR, hazard ratio; CI, confidence interval; NE, not estimable.</p>a<p>P values for age at diagnosis, CA125 and HER2 amplification ratio were based on Wald test, and P values for all other variables were based on the log-rank test.</p>b<p>Based on Wald test.</p>c<p>To interpret with caution as there were <10 deaths in the fitted multivariable model.</p
HER2 amplification, age, and frequency of cancers reported in family history of mEOC.
<p>(A) Previous genome-wide copy number alteration study on a small cohort of mEOC (n = 17) showed significant amplification of HER2. x-axis shows chromosomes 1-X, with alternating gray blocks. y-axis is the −log(q) where q is the false discovery rate. Positive values indicate amplification and negative values are deletion. (B) Age distribution was of normal distribution overall and for both HER2+ and HER2− cases. The median age was 48.3 (range: 15 to 89 years). (C) Frequency of reported cancers in family history. Majority of cancers were of breast and gastrointestinal (colon/stomach) origin. Note: some patients reported more than 1 case of cancer in family history.</p
Survival outcomes by HER2 status.
<p>No statistical significance was observed for HER2+ compared to HER2− cases in (A) overall survival (log-rank p = 0.249), and (B) progression free survival (log-rank p = 0.120).</p
A genomic-augmented multivariate prognostic model for the survival of Natural-killer/T-cell lymphoma patients from an international cohort.
10.1002/ajh.26636Am J Hemato